Playing Nice: Infection Control and Clinical Microbiology in the Pay-For-Performance Era

One specific area where understanding competing goals is critically important is the interplay between the increasing sensitivity and precision of microbiologic tests and the growing pressure to reduce HAI. As you can imagine, with 3% of CMS payments potentially at risk, anything that could impact HAI rates in a negative fashion is bound to be a flashpoint for hospital administrators. With that in mind, I point you to Dan's excellent commentary just published in JCM that examines the implications of advances in microbiological testing on HAI rates and provides specific suggestions for how hospital epi programs and clinical microbiology labs can work together to respond to these changes.
Initially, Dan provides three scenarios where changes in the micro lab could directly impact HAI rates (1) The effect of MALDI-TOF on CLABSI rates (2) The shift from EIA to nucleic-acid amplification tests (NAAT) for C. difficile detection and (3) Pressure to block urine culture ordering to reduce CAUTI. After delving into the current CMS reimbursement landscape, the unintended consequences of improvements in diagnostic testing and the use/misuse of surveillance definitions, he provides six valuable recommendations that clinical microbiology labs (CML) and infection prevention programs (IPP) should consider:
(1) CML leadership should select diagnostic approaches with the goal of improving individual patient outcomes
(2) Hospital and IPP leadership should not pressure the CML to alter diagnostic practices based on the need to demonstrate lower HAI rates for pay-for-performance measures.
(3) Public health authorities (CDC/NHSN) must be proactive in adjusting HAI metrics to changing CML technology
For recommendations 4-6, you're gonna have to read his commentary. But a hint at #6 - CML and IPP leadership need to collaborate and advocate for their needs, because, unlike at Iowa, both sides aren't always present in the mind of a single person.
Initially, Dan provides three scenarios where changes in the micro lab could directly impact HAI rates (1) The effect of MALDI-TOF on CLABSI rates (2) The shift from EIA to nucleic-acid amplification tests (NAAT) for C. difficile detection and (3) Pressure to block urine culture ordering to reduce CAUTI. After delving into the current CMS reimbursement landscape, the unintended consequences of improvements in diagnostic testing and the use/misuse of surveillance definitions, he provides six valuable recommendations that clinical microbiology labs (CML) and infection prevention programs (IPP) should consider:
(1) CML leadership should select diagnostic approaches with the goal of improving individual patient outcomes
(2) Hospital and IPP leadership should not pressure the CML to alter diagnostic practices based on the need to demonstrate lower HAI rates for pay-for-performance measures.
(3) Public health authorities (CDC/NHSN) must be proactive in adjusting HAI metrics to changing CML technology
For recommendations 4-6, you're gonna have to read his commentary. But a hint at #6 - CML and IPP leadership need to collaborate and advocate for their needs, because, unlike at Iowa, both sides aren't always present in the mind of a single person.
Comments
Post a Comment
Thanks for submitting your comment to the Controversies blog. To reduce spam, all comments will be reviewed by the blog moderator prior to publishing. However, all legitimate comments will be published, whether they agree with or oppose the content of the post.